Can sound, heat, and pressure rewire the depressed brain?

NCT ID NCT07800663

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

Researchers are testing whether a series of multisensory stimulation sessions can reduce depressive symptoms in adults with moderate-to-severe depression. Fifteen participants receive nine 20-minute sessions combining auditory, thermal, and pressure stimuli, calibrated to about 60% of each person's pain threshold. The team measures mood, rumination, and resilience before, during, and after the sessions. The goal is to see whether this bottom-up sensory approach offers a safe new way to ease depression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sensory hyperstimulation: nine 20-minute sessions combining auditory, thermal, and pressure stimuli calibrated to about 60% of each person's pain threshold
What this could lead to
If it works, this could point toward a drug-free, side-effect-light option for people with depression who do not respond to standard treatments.
What could go wrong
This is a very small, early, open-label study with no placebo group, so results may not hold up in larger trials. The stimulation is set near pain thresholds, which may cause discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Apr 2021

Finished

Apr 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis of Major Depressive Disorder (MDD) according to DSM-5 * age ≥18 * baseline Hamilton Depression Rating Scale score (HAMD-17) \> 17. Exclusion Criteria: * Patients with Schizophrenia disorder and/or Active Psychosis. * Patients with serious physical morbidity (patents with unbalanced hypertension or diabetes). * Patients with ischemic heart disease. * Patients with chronic pain disorder or treatment regulary with pain killers (acamol etc) opioids or medical cannabis. * Active substance abuse (drugs or alcohol) two weeks before the study. * Sensory processing syndrome * Post traumatic stress disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tel-Aviv University

    Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.